Cancer Treatment in China: What Works, What Doesn't, and Real Costs
Cancer care in China is stage, histology and biomarkers first, not a hospital slogan. Satri-cel is a narrow gastric/GEJ CAR-T after two lines, not a solid-tumour cure. SPHIC has published a particle course of RMB 278,000. Send pathology; we match the file in about 24 hours. No obligation to book.
Average reply: 24 hoursNo obligation to book
Stage firstnot a hospital slogan
NMPA labelsnarrow, not universal
RMB 278k beamSPHIC published fee
Quick answer
Cancer care in China is stage, histology and biomarkers first, not a hospital slogan. NCCN maps (widely downloaded in China) plus NMPA labels decide what is ordinary care, what is a labelled cell product, and what is a trial. There is no single “China cancer package.” Public academic centres (CAMS/NCC, PKU Cancer, Fudan, SYSUCC, Ruijin) are the usual shortlist. Satri-cel is a narrow gastric/GEJ CAR-T after two lines, not a solid-tumour cure. Send pathology and staging. We match the file. About 24 hours. No obligation to book.
Approved care, trials, and marketing — labelled
NMPA-APPROVED (SELECTED)
Blood-cancer CAR-T
CD19 for selected B-cell leukaemias/lymphomas. BCMA for selected relapsed or refractory myeloma. Centre protocols still apply.
NARROW SOLID-TUMOUR LABEL
Satri-cel (gastric / GEJ)
Claudin18.2-positive, HER2-negative, advanced gastric or GEJ, at least two prior lines. Not CAR-T for every solid tumour. CAR-T page
INVESTIGATIONAL / SELECTED
Proton, heavy-ion, TIL, TCR-T
Particle therapy is indication-specific. TIL/TCR-T stay trial-only. Proton page
Named centres used in file reviews
These are comparison points, not a ranking and not an automatic admission. We shortlist after pathology and staging.
Cancer Hospital, CAMS / NCC — Beijing
National cancer centre. Broad oncology and a large trial footprint.
Peking University Cancer Hospital — Beijing
Cellular therapy; satri-cel / CT041 programme often referenced here.
High-volume comprehensive oncology; immunotherapy and solid tumours.
Ruijin Hospital — Shanghai
Haematology, CAR-T, and a proton programme. Blood-cancer files often start here.
Nasopharyngeal, liver and GI strength; active trial list. Compare with Fuda only after the method fits.
SPHIC + Tianjin Cancer
SPHIC: proton and carbon-ion. Tianjin: large dedicated cancer hospital. Particle questions go to the proton page.
Indicative planning ranges (not an invoice)
Figures compiled from public patient-navigation sources and hospital self-pay discussions. Confirm with the treating centre. Stay, drugs, ICU and complications are usually extra.
| Pathway | Planning range | Usually excludes |
|---|---|---|
| Selected public-hospital CAR-T (blood cancers) | from about USD 25,000 | bridging, ICU, long stay |
| Private-hospital CAR-T (blood cancers) | about USD 70,000-90,000 | complication care, extra cycles |
| Satri-cel cellular product only | about RMB 990,000 / USD 146,000 | admission, lymphodepletion, toxicity |
| Proton course | about USD 20,000-35,000 | hotel weeks, extra imaging, inpatient |
| Complex commercial CAR-T packages | up to about USD 170,000-200,000 | combined transplant plans can be higher |
Cost drivers page · How we choose hospitals · CAR-T detail · Proton detail
What actually changes the plan
📋
Methods with an evidence label
Surgery, systemic therapy, proton/heavy-ion, approved CAR-T (CD19, BCMA, narrow satri-cel) vs trial-only cell programmes.
🏥
Named centres, not a ranking poster
CAMS/NCC, PKU Cancer, Fudan, Ruijin, SYSUCC, Tianjin, SPHIC, Fuda — shortlisted by tumour type and technology, not by ads.
✈️
Cost drivers and logistics
Indicative USD/RMB bands, what a quote must itemise, visa invitation, interpreter and stay after a hospital will see you.
What this page helps you decide
✅
Diagnosis-first matching
Stage, pathology and biomarkers decide the department. A famous hospital name is not a plan.
💬
Approved vs investigational
We label satri-cel, blood-cancer CAR-T, proton and trials separately so a headline does not become a booking.
🌍
Honest stage-4 goals
Control and quality of life when cure is not the endpoint. No false promises for advanced disease.
Evidence table
IARC burden, NMPA labels, Lancet satri-cel PFS, SPHIC published fee.
| Source | What it says | Relevance to patients |
|---|---|---|
| IARC GLOBOCAN China (2024) | Lung 1,175,915 cases / 743,336 deaths; liver 2nd in deaths | Volume is real. Volume is not a ranking of your file. |
| NCCN guidelines (current) | Stage and biomarker maps; China is a high-download country | Ask the centre which map they are following. |
| NMPA satri-cel label (22 Jun 2026) | CLDN18.2+, HER2-, G/GEJA, ≥2 prior lines | Not CAR-T for every solid tumour. |
| Lancet satri-cel phase 2 (2025-26) | PFS 3.25 vs 1.77 months; high-grade AE 99% | Modest PFS, heavy toxicity, selected patients. |
| SPHIC fee reporting (2015-) | RMB 278,000 particle course; ~RMB 330,000 inpatient total | Local therapy. Not a blood-cancer product. |
Who this page is for
Solid-tumour patients
Lung, liver, GI, breast, prostate, gastric including the narrow satri-cel screen, and other localisations with a complete file.
Blood-cancer and CAR-T candidates
Selected leukaemias, lymphomas and myeloma where CD19 or BCMA CAR-T may be commercially available at designated centres.
Families facing stage-4 decisions
Need realistic goals, a cost-driver list and a hospital that will actually accept the case — not a cure slogan.
What you can actually book
Histology, stage, prior lines and the relevant panel (EGFR, ALK, PD-L1, HER2, CLDN18.2, BRCA, and others as relevant), then a shortlist of public MDTs. Organ pages: lung, breast, liver, stomach / satri-cel, prostate, CAR-T, proton, Fuda, cost.
What moves the cost
Oncology case review
No charge to start
Organ pathway • Approved vs trial label • First hospital shortlist • Records checklist
Coordinated treatment trip
Quoted after records
Hospital matching • Indicative USD/RMB bands • Visa support • Interpreter • On-site coordination
These are routing steps, not a hospital package SKU. Published procedure examples stay in the evidence/cost sections only when a source exists. Hospital, drugs, stay, interpreter and travel are quoted separately after records.
What happens next
01
Send the oncology file
Pathology, imaging, molecular results, prior lines and your goal (second opinion, CAR-T screen, proton, or travel plan).
02
Compare centres and evidence level
Which hospitals, which method, approved vs trial, timelines and a written cost-driver range.
03
Travel only if accepted
Invitation letter, visa path, interpreter and stay — after a named team is willing to review the case.
Request a preliminary case review
Tell us the basics of your case. When you submit, WhatsApp will open with the information you entered so you can review it before sending. This is a preliminary routing request, not a diagnosis, treatment acceptance, trial enrollment, visa decision, or medical advice.
Frequently asked questions
How much does cancer treatment cost in China?
There is no single price. SPHIC has published RMB 278,000 for a particle course (typical inpatient totals around RMB 330,000). Public blood-cancer CAR-T navigator bands often start in the mid five-figure USD range; private packages often about USD 70,000-90,000. Satri-cel product has been cited around RMB 990,000 before stay and ICU.
What is satri-cel?
NMPA-approved 22 June 2026 CAR-T for CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma after at least two prior lines. Lancet phase 2: PFS 3.25 vs 1.77 months; grade 3 or higher adverse events in 99%.
Which hospitals do you shortlist?
Usually CAMS/NCC, Peking University Cancer Hospital, Fudan Shanghai Cancer Center, Ruijin, SYSUCC, and SPHIC when the question is a particle beam. Fuda is compared, not treated as the default.
Is CAR-T available for every solid tumour?
No. Labelled solid-tumour CAR-T is satri-cel in a narrow gastric/GEJ group. Other solid-tumour cell programmes need a trial ID.
Do you rank the best cancer hospital in China?
No. Volume and labels are not a ranking that replaces an MDT on your slides.
What records should I send?
Pathology, staging CT/MRI/PET, biomarker panel, prior lines, and the package or paper you were shown.
Is Fuda the default China cancer hospital?
No. It is a private, internationally marketed centre. Compare method and stage with a public MDT.
Do you promise a cure?
No. We match files. Average reply about 24 hours. No obligation to book.
Do I pay before you read the file?
No. Payment required before a file review is a red flag. Average reply about 24 hours. No obligation to book.
How fast do you reply?
About 24 hours. We label the file as labelled care, trial, or marketing. No obligation to book.
Red flags in offers
Overseas ads often sell “best cancer hospital in China” or a Fuda-shaped ablation package. Navigator cost bands for CAR-T run from mid five-figure USD in some public blood-cancer rooms to ~USD 70,000-90,000 private packages; satri-cel product has been cited around RMB 990,000 before stay and ICU. Those figures are not our invoice. A brand name is a door, not a diagnosis.
No pathology, no stage, but a package price.
One clinic for “all cancers” plus stem cells plus diabetes.
CAR-T offered for a solid tumour with no biomarker and no trial ID.
Pay before DICOM and slides are read.
Sources
IARC/WHO GLOBOCAN 2024 China fact sheet.
NCCN clinical practice guidelines; NCCN public note on use in China.
NMPA satri-cel approval 22 June 2026; Lancet phase 2 PFS/toxicity figures.
SPHIC / municipal reporting of the RMB 278,000 particle-course fee.
Public descriptions of CAMS/NCC, PKU Cancer, FUSCC, SYSUCC, Ruijin.
Freshness label on this page: 2026-08-15
Medical note
A treating oncologist in your home country should review imaging and pathology before you travel. This page is matching information, not a treatment recommendation.